Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) increased the supply and demand gap of experimental monkeys by more than 4% or continued to expand the company's high-quality scarce experimental monkey resources

The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) rose by more than 4%. As of press release, it had risen 3.36% to HK$24, with a turnover of HK$108 million.

According to the news, according to media reports, the price of crab-eating monkeys around the age of 3-5 has now risen to 140,000 yuan each, and supply is already in short supply during the year. Changjiang Securities released a research report saying that currently, the supply side of experimental monkeys continues to decline, the demand side is recovering steadily, and most of the new technologies such as small nucleic acid and CAR-T also require the use of experimental monkeys to increase the structured share. The gap between supply and demand for experimental monkeys may continue to widen, and the price of monkeys is also beginning to show an upward trend.

The bank pointed out that Zhaoyan New Pharmaceutical has high-quality and scarce experimental monkey resources. On the one hand, the monkey farm releases a certain number of experimental monkeys for the company to use every year to contribute to the basic profit market; on the other hand, in the context of increasingly tight supply of experimental monkeys, mastering high-quality experimental monkey resources may have a stronger voice, or even enjoy service fee premiums.